WINTON GROUP Ltd Has $259,000 Holdings in Nektar Therapeutics (NASDAQ:NKTR)

WINTON GROUP Ltd increased its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 7.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,283 shares of the biopharmaceutical company’s stock after buying an additional 532 shares during the quarter. WINTON GROUP Ltd’s holdings in Nektar Therapeutics were worth $259,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Northwestern Mutual Investment Management Company LLC raised its stake in shares of Nektar Therapeutics by 1.5% in the 1st quarter. Northwestern Mutual Investment Management Company LLC now owns 26,456 shares of the biopharmaceutical company’s stock valued at $889,000 after purchasing an additional 395 shares during the period. TD Asset Management Inc. raised its stake in shares of Nektar Therapeutics by 0.5% in the 1st quarter. TD Asset Management Inc. now owns 84,241 shares of the biopharmaceutical company’s stock valued at $2,830,000 after purchasing an additional 427 shares during the period. Mason Street Advisors LLC raised its stake in shares of Nektar Therapeutics by 1.8% in the 1st quarter. Mason Street Advisors LLC now owns 24,838 shares of the biopharmaceutical company’s stock valued at $835,000 after purchasing an additional 436 shares during the period. Meeder Asset Management Inc. raised its stake in shares of Nektar Therapeutics by 150.2% in the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 479 shares during the period. Finally, State Treasurer State of Michigan raised its stake in shares of Nektar Therapeutics by 1.2% in the 1st quarter. State Treasurer State of Michigan now owns 50,200 shares of the biopharmaceutical company’s stock valued at $1,687,000 after purchasing an additional 600 shares during the period. 92.14% of the stock is currently owned by institutional investors and hedge funds.

In related news, CAO Jillian B. Thomsen sold 1,928 shares of Nektar Therapeutics stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $60,481.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Stephen K. Doberstein sold 3,461 shares of Nektar Therapeutics stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $31.37, for a total value of $108,571.57. Following the transaction, the senior vice president now owns 95,913 shares of the company’s stock, valued at approximately $3,008,790.81. The disclosure for this sale can be found here. Insiders sold a total of 253,283 shares of company stock valued at $8,356,254 in the last 90 days. 4.02% of the stock is owned by corporate insiders.

Shares of NASDAQ NKTR traded down $0.10 during mid-day trading on Friday, hitting $31.09. The company had a trading volume of 2,336,162 shares, compared to its average volume of 1,457,576. The company has a market cap of $5.44 billion, a P/E ratio of 8.22 and a beta of 2.68. The company has a 50-day moving average price of $33.40. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. Nektar Therapeutics has a one year low of $28.04 and a one year high of $69.76.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. The company had revenue of $28.22 million during the quarter, compared to analysts’ expectations of $25.45 million. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. During the same quarter last year, the company earned ($0.60) EPS. On average, sell-side analysts forecast that Nektar Therapeutics will post -3.13 earnings per share for the current year.

NKTR has been the topic of several recent research reports. William Blair reissued a “buy” rating on shares of Nektar Therapeutics in a research note on Friday, June 14th. Cowen set a $82.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a research note on Thursday, June 13th. BidaskClub downgraded Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 16th. Zacks Investment Research downgraded Nektar Therapeutics from a “buy” rating to a “hold” rating and set a $34.00 price target on the stock. in a research note on Wednesday. Finally, ValuEngine raised Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $67.60.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

See Also: Correction

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.